Synthetic methods and intermediates for steroisomeric...

Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

Reexamination Certificate

active

07629466

ABSTRACT:
The subject invention provides methods and/or processes for making stereoisomeric compounds of formula (X):wherein the variables are as defined herein, and compositions for the safe and effective treatment of various gastrointestinal disorders including, but not limited to, gastroparesis, gastroesophageal reflux and related conditions. The compounds of the subject invention are also useful in treating a variety of conditions involving the central nervous system.

REFERENCES:
patent: 3536809 (1970-10-01), Applezweig
patent: 3598123 (1971-08-01), Zaffaroni
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 4008719 (1977-02-01), Theeuwes et al.
patent: 4870074 (1989-09-01), Kon et al.
patent: 4962115 (1990-10-01), Van Daele
patent: 4975439 (1990-12-01), Van Daele et al.
patent: 5041454 (1991-08-01), Van Daele et al.
patent: 5057525 (1991-10-01), Van Daele et al.
patent: 5137896 (1992-08-01), Van Daele
patent: 5395832 (1995-03-01), Ito et al.
patent: 5423872 (1995-06-01), Cigaina
patent: 5500422 (1996-03-01), Ito et al.
patent: 5618828 (1997-04-01), Gray et al.
patent: 5629328 (1997-05-01), Gray et al.
patent: 5629329 (1997-05-01), Gray et al.
patent: 5705498 (1998-01-01), Gaster et al.
patent: 5712293 (1998-01-01), McCullough et al.
patent: 5739151 (1998-04-01), McCullough et al.
patent: 5877188 (1999-03-01), McCullough et al.
patent: 5877189 (1999-03-01), McCullough et al.
patent: 5955477 (1999-09-01), Gray et al.
patent: 5955478 (1999-09-01), Gray et al.
patent: 6066654 (2000-05-01), Gray et al.
patent: 6114356 (2000-09-01), McCullough et al.
patent: 6147093 (2000-11-01), McCullough et al.
patent: 6242465 (2001-06-01), McCullough et al.
patent: 6331401 (2001-12-01), Christophe et al.
patent: 6552046 (2003-04-01), Druzgala et al.
patent: 6632827 (2003-10-01), McCullough et al.
patent: 6638951 (2003-10-01), Kato et al.
patent: 7176218 (2007-02-01), Irwin et al.
patent: 7282509 (2007-10-01), Irwin et al.
patent: 7326787 (2008-02-01), By et al.
patent: 2003/0216387 (2003-11-01), Druzgala et al.
patent: 2004/0092511 (2004-05-01), Billstein et al.
patent: 19933926 (2001-01-01), None
patent: 0076530 (1983-04-01), None
patent: 0309043 (1989-03-01), None
patent: 0640601 (1994-03-01), None
patent: 1149832 (2001-10-01), None
patent: 1325921 (2003-09-01), None
patent: 1425706 (1976-02-01), None
patent: 11292846 (1999-10-01), None
patent: 99/02496 (1999-01-01), None
patent: 01/93849 (2001-10-01), None
patent: 2005/068461 (2005-07-01), None
patent: 2007/028073 (2007-03-01), None
Van Daele et al. Drug Development Research (1986), 8(1-4), 225-32.
Scott et al., “Tegaserod,” Drugs, 58:491-496 (1999).
Nagakura et al., “The seclective 5-hydroxytryptamine (5-HT) 4-receptor agonist RS67506 enhances lower intestinal propulsion in mice,” Japanese Journal of Pharmacology, 74:209-212 (1997).
Paakkari et al., “Cardiotoxicity of new anithistamines and cisapride,” Toxicology Letters, 127:279-284 (2002).
Horowitz et al., “Relationship between the effects of Cisapide on gastric emptying and plasma glucose concentrations in diabetic gastroparesis,” Digestion, 65:41-46 (2002).
Barnes, N. M., “Identification of 5-HT.sub.3 recognition sites in the ferret area postrema,” J. Pharm. Pharmacol., 40:586-588 (1998).
Decktor et al., “Effect of metoclopramide, bethanechol and the cholecystokinin receptor antagonist, L-364,718, on gastric emptying in the rat,” European Journal of Pharmacology, 147:313-316 (1988).
Stacher et al., “Effects of Oral Cisapride on Interdigestive jejunal Motor Activity, Psychomotor Function, and Side-Effect Profile in Healthy Man,” Digestive Diseases and Sciences, 32(11):1223-1230 (1987).
Van Daele et al., “Synthesis of Cisapride, a Gastrointestinal Stimulant Derived from Cis-4-Amino-3-Methoxypiperidine,” Drug Development Research, 8:225-232 (1986).
Sanger et al., “Preparation of substituted indo1-3-yl . . . ”, CA 119:72611 (1993).
Dean et al., “No change in the density of serotonin 1a . . . ” CA 131:30595 (1999).
Sakurai et al., “Involvement of the 5-hydroxytriptamine 4 . . . ” CA 139:115744 (2003).
Stoinov et al., “Evaluation of the effects of the medications . . . ” CA 135:251747 (2001).
Ohuchi et al., “Preparation of quinolinecarboxylic . . . ” CA 124:202043 (1996).
Hirokawa et al., “New substitued pyridine carboxamide derivative or its acid salt useful as digestive tract function improving agent and serotonin reeptor agonist,” Database WPI Week 200532, Derwent Publications LTD., Apr. 21, 2005 (XP002411554).
Kato et al., “New substituted piperidinyl pyridine carboxamide derivative or its acid added salt useful as digestive tract fucntion improving agent and serotonin receptor agonist,” Database WPI Week 200528, Derwent Publications LTD., Mar. 31, 2005 (XP002411553).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Synthetic methods and intermediates for steroisomeric... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Synthetic methods and intermediates for steroisomeric..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synthetic methods and intermediates for steroisomeric... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4092423

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.